Expanding the therapeutic landscape of still's disease: the emerging role of JAK inhibitors [0.03%]
Still病治疗领域拓宽：JAK抑制剂的新兴作用
Piero Ruscitti,Francesco Ursini,Roberto Giacomelli et al.
Piero Ruscitti et al.
Introduction: Still's disease is a systemic inflammatory disorder characterized by a complex cytokine network involving interleukin (IL)-1, IL‑6, IL‑18 and interferon (IFN)-γ. Although IL‑1 and IL‑6 inhibitors repres...
Pearls and pitfalls of oral carbapenem/penem agents: the promise of a new era or the risk of amplified resistance? [0.03%]
口服碳青霉烯和氧青霉烷类药物的机遇与风险：新时代的希望还是加剧耐药性的危险？
Muhammed Cihan Işık,Murat Akova
Muhammed Cihan Işık
Introduction: The rising prevalence of MDR Gram-negative infections, particularly ESBL-producing Enterobacterales, has created a critical oral treatment gap, necessitating prolonged intravenous therapy. Oral carbapenems/p...
Current poly(adenosine diphosphate-ribose) polymerase inhibitors (PARPi) in metastatic prostate cancer: uses and controversies [0.03%]
转移性前列腺癌中当前的多聚(腺苷二磷酸核糖)聚合酶抑制剂(PARPi)：应用与争议
Farhan Azad,Eseoghene Kevu,Jeanny B Aragon-Ching
Farhan Azad
Advances and controversies in chronotherapy in management of adult hypertension [0.03%]
成人高血压管理中时间治疗学的进展和争议
Mark Y Lee,Michael Safani
Mark Y Lee
Evaluating sparsentan for the treatment of focal segmental glomerulosclerosis [0.03%]
评估司帕森坦治疗局灶节段性肾小球硬化症的效果
Cristián Juanet,María José Soler,Ladan Zand et al.
Cristián Juanet et al.
Introduction: Focal segmental glomerulosclerosis (FSGS) represents a histopathologic pattern of glomerular injury rather than a single disease entity. In FSGS, prognosis varies substantially according to the degree of pro...
East meets West: resectable gastric cancer treatment in the era of immune checkpoint inhibitors [0.03%]
东西方可切除胃癌免疫检查点抑制剂时代治疗差异
Ruwani Mawella,Hyung-Don Kim,Raghav Sundar et al.
Ruwani Mawella et al.
Introduction: Resectable gastric cancer remains a major global health challenge, with significant geographic variation in treatment paradigms between Eastern and Western practice. While perioperative chemotherapy has been...
New and novel pharmacotherapies for hemophilia A: an update [0.03%]
新型重组凝血因子 VIII 产品及治疗 A 型血友病的在研新药进展更新
Anna Chiara Giuffrida,Daniele Focosi,Marco Bodini et al.
Anna Chiara Giuffrida et al.
Introduction: Hemophilia A (HA) management has progressed significantly, yet standard and extended half-life (EHL) clotting factors present persistent limitations, including intravenous burden and suboptimal trough levels...
Updated ocular pharmacology for noninfectious uveitis: a comprehensive expert review [0.03%]
非感染性葡萄膜炎的眼科药理学最新进展：全面专家回顾
Matthew D Spangler,Nila Kirupaharan,John D Sheppard
Matthew D Spangler
Introduction: Uveitis encompasses a heterogeneous group of inflammatory disorders affecting the iris, ciliary body, and choroid and remains a leading cause of preventable blindness worldwide. Although corticosteroids have...
Emerging pharmacotherapies for chronic spontaneous urticaria: spotlight on BTK inhibitors [0.03%]
慢性自发性荨麻疹的新兴药物疗法：聚焦布鲁顿酪氨酸激酶抑制剂
Ozge Sevil Karstarli Bakay,Emek Kocatürk
Ozge Sevil Karstarli Bakay
Introduction: Chronic spontaneous urticaria (CSU) results from multiple interacting pathogenic mechanisms. Despite available treatments, a proportion of patients remain inadequately controlled, supporting the need for the...
Management of patients with thymidine kinase 2 deficiency: where are we now? [0.03%]
核苷酸激酶2缺乏症患者的管理：我们目前处在什么阶段？
Cristina Domínguez-González
Cristina Domínguez-González